Pliant Therapeutics (PLRX)
NASDAQ:PLRX
Want to see PLRX full AI Analyst Report?
Top Page
Pliant Therapeutics
(NASDAQ:PLRX)
Select Model
Select Model
Rating:49Neutral
Price Target:
$1.00
▼(-24.81% Downside)
Action:ReiteratedDate:03/12/26
The score is primarily held back by weak financial performance—ongoing losses, consistent negative free cash flow, and a shrinking equity cushion. Technicals provide some support via improving short-term momentum, but longer-term trend signals remain soft, and valuation is constrained by negative earnings and no stated dividend yield.
Positive Factors
Modest leverage
Low reported leverage reduces near-term solvency risk versus many cash-burning biotech peers, preserving optionality to fund ongoing clinical programs. This structural balance sheet strength makes bankruptcy risk lower and gives management more time to advance trials before needing debt financing.
Negative Factors
Persistent cash burn
Negative operating and free cash flow each year indicates the business consumes cash to advance programs, and worsening FCF in 2025 signals accelerating burn. Over months this forces dependence on external financing, raising dilution risk and potentially slowing development if capital access tightens.
Read all positive and negative factors
Positive Factors
Negative Factors
Modest leverage
Low reported leverage reduces near-term solvency risk versus many cash-burning biotech peers, preserving optionality to fund ongoing clinical programs. This structural balance sheet strength makes bankruptcy risk lower and gives management more time to advance trials before needing debt financing.
Read all positive factors
Pliant Therapeutics (PLRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$76.77M
Dividend YieldN/A
Average Volume (3M)581.13K
Price to Earnings (P/E)―
Beta (1Y)1.19
Revenue GrowthN/A
EPS Growth29.91%
CountryUS
Employees171
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.38
Shares Outstanding61,914,665
10 Day Avg. Volume902,150
30 Day Avg. Volume581,135
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-0.58
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-46.49
Enterprise Value/Ebitda-0.39
Forecast
1Y Price Target
$2.67Price Target Upside100.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.51
Revenue Forecast (FY)N/A
Pliant Therapeutics Business Overview & Revenue Model
Company Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an ora...
How the Company Makes Money
Pliant Therapeutics does not have commercialized products and is primarily a development-stage company; as a result, it has historically generated little to no recurring product revenue. Its funding and any reported revenue typically come from (a)...
Pliant Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 1.58M | 9.69M | 7.57M |
| Gross Profit | -1.70M | 0.00 | 1.58M | 9.69M | 7.57M |
| EBITDA | -148.38M | -205.16M | -158.23M | -118.85M | -95.73M |
| Net Income | -149.34M | -210.30M | -161.34M | -123.32M | -97.26M |
Balance Sheet | |||||
| Total Assets | 225.23M | 396.95M | 512.15M | 350.61M | 221.22M |
| Cash, Cash Equivalents and Short-Term Investments | 190.94M | 355.72M | 494.25M | 331.19M | 200.60M |
| Total Debt | 29.11M | 60.19M | 11.37M | 15.81M | 7.19M |
| Total Liabilities | 44.02M | 92.87M | 38.58M | 37.27M | 22.16M |
| Stockholders Equity | 181.21M | 304.08M | 473.58M | 313.34M | 199.06M |
Cash Flow | |||||
| Free Cash Flow | -128.71M | -159.35M | -117.28M | -96.39M | -77.40M |
| Operating Cash Flow | -128.34M | -155.50M | -116.36M | -94.63M | -75.44M |
| Investing Cash Flow | 134.29M | 140.34M | -127.01M | -150.20M | 73.70M |
| Financing Cash Flow | -31.70M | 23.12M | 274.40M | 226.85M | 2.53M |
Pliant Therapeutics Technical Analysis
Positive
1.33
Price Trends
1.27
Positive
1.29
Positive
1.43
Negative
Market Momentum
<0.01
Negative
53.92
Neutral
42.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLRX, the sentiment is Positive. The current price of 1.33 is above the 20-day moving average (MA) of 1.29, above the 50-day MA of 1.27, and below the 200-day MA of 1.43, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.92 is Neutral, neither overbought nor oversold. The STOCH value of 42.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PLRX.
Pliant Therapeutics Risk Analysis
Pliant Therapeutics disclosed 83 risk factors in its most recent earnings report. Pliant Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pliant Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $449.90M | -6.90 | -23.98% | ― | 1181.27% | 29.56% | |
61 Neutral | $155.72M | 1.57 | 43.14% | ― | ― | ― | |
52 Neutral | $136.57M | -6.36 | -119.19% | ― | -100.00% | -123.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $76.77M | -0.50 | -69.56% | ― | ― | 29.91% | |
49 Neutral | $106.99M | -1.32 | -81.77% | ― | ― | ― | |
42 Neutral | $22.17M | -2.00 | 7743.57% | ― | ― | -25.06% |
* Healthcare Sector Average
PLRX
Pliant Therapeutics
1.21
-0.27
-18.24%
ORMP
Oramed Pharm
4.11
1.94
89.23%
OVID
Ovid Therapeutics
2.69
2.35
695.86%
IFRX
InflaRx
1.61
0.16
11.03%
EQ
Equillium
2.04
1.60
363.64%
QNCX
Quince Therapeutics
1.29
-10.01
-88.58%
Pliant Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Pliant Therapeutics Announces Board Retirements and Option Repricing
Neutral
Apr 17, 2026
Pliant Therapeutics announced that on April 14 and April 16, 2026, directors David E.I. Pyott and Katharine Knobil, M.D., notified the company of their plans to retire from its board and committees effective at the 2026 Annual Meeting of Stockhold...
Business Operations and StrategyPrivate Placements and Financing
Pliant Therapeutics Launches New $50 Million ATM Program
Neutral
Mar 30, 2026
On March 30, 2026, Pliant Therapeutics, Inc. entered into a new Sales Agreement with Leerink Partners LLC to establish an at-the-market equity program, allowing the company to sell up to $50 million of its common stock from time to time through th...
Business Operations and StrategyRegulatory Filings and Compliance
Pliant Therapeutics Extends Stockholder Rights Agreement Expiration
Neutral
Mar 4, 2026
On March 3, 2026, Pliant Therapeutics, Inc. amended its Stockholder Rights Agreement with Computershare Trust Company, N.A., extending the final expiration of the shareholder rights from March 11, 2026, to March 11, 2027, while leaving other core ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.